Corporate GovernanceApr 30, 2026, 04:46 PM
VXRT 10-K/A Details Board, Executive Officers, Governance
AI Summary
Vaxart, Inc. filed Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2025, primarily to include information required by Part III. This section details the company's executive officers, directors, and corporate governance practices, including board independence and committee structures. The filing also noted the aggregate market value of non-affiliate common stock was $102,712,906 as of June 30, 2025, with 240,634,372 shares outstanding as of March 6, 2026.
Key Highlights
- Filed Amendment No. 1 to 2025 Form 10-K, solely for Part III information.
- Part III includes Directors, Executive Officers, and Corporate Governance details.
- Non-affiliate common stock market value was $102,712,906 as of June 30, 2025.
- 240,634,372 common shares outstanding as of March 6, 2026.
- All directors, except CEO Steven Lo, are independent per Nasdaq standards.
- Board maintains separate Lead Director (W. Mark Watson) and CEO roles.
- Audit Committee chaired by W. Mark Watson; Compensation by Dr. David Wheadon; Nominating & Governance by Dr. Elaine J. Heron.
- Science and Technology Committee was disbanded on September 30, 2025.
Price Impact
More from VXRT